Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.

Muller AF, Janssen JA, Lamberts SW, Bidlingmaier M, Strasburger CJ, Hofland L, van der Lely AJ

Clinical endocrinology1 Oct 2001Cited by 10 (Europe PMC)

PMID11678828DOI10.1046/j.1365-2265.2001.01374.xPepBankPUB-11678828

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy lean men, pegvisomant combined with fasting had a synergistic effect on GHRP-6-stimulated GH release, compared with fasting alone and pegvisomant alone.
In plain wordsIn healthy lean men, pegvisomant and fasting together had a synergistic effect on GH release after GHRP-6, compared with either alone.
Peptide
Pegvisomant
Outcome
IncreaseGHRP-6-stimulated GH release during fasting
Study
n = 10
Comparator
Fasting alone and pegvisomant alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 mg as a single injection · subcutaneousAs given in this study (human).
Source sentences
Summary
The combination of fasting and pegvisomant had a synergistic effect on GH release after GHRP-6.
5 context sentences(design, population, supporting numbers)
Summary · context
Fasting alone increased GH levels after GHRP-6 administration.
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
Summary · context
We also performed a single-arm open label study under nonfasting conditions in five of these subjects.
Summary · context
After the second test either pegvisomant (80 mg as a single subcutaneous injection) or placebo was administered.
Summary · context
On day 4, GHRP-6 and GHRH tests were performed in the same order as on day 1.
Report a problemFND-1167882809
02HumanNon-randomized trialEfficacy outcome
In healthy lean men, pegvisomant alone increased GH concentrations.
In plain wordsIn healthy lean men, GH concentrations increased after pegvisomant alone.
Peptide
Pegvisomant
Outcome
IncreaseGH concentration with pegvisomant alone
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 mg as a single injection · subcutaneousAs given in this study (human).
Source sentences
Summary
Three days of fasting alone and pegvisomant alone as well as in combination increased GH concentrations, whereas a decrease in serum-free, but not total, IGF-I concentrations was observed.
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
Summary · context
We also performed a single-arm open label study under nonfasting conditions in five of these subjects.
Summary · context
After the second test either pegvisomant (80 mg as a single subcutaneous injection) or placebo was administered.
Summary · context
On day 4, GHRP-6 and GHRH tests were performed in the same order as on day 1.
Report a problemFND-1167882804
03HumanNon-randomized trialEfficacy outcome
In healthy lean men, pegvisomant alone decreased serum free IGF-I concentrations.
In plain wordsIn healthy lean men, free IGF-I concentrations decreased after pegvisomant alone.
Peptide
Pegvisomant
Outcome
DecreaseSerum free IGF-I with pegvisomant alone
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 mg as a single injection · subcutaneousAs given in this study (human).
Source sentences
Summary
Three days of fasting alone and pegvisomant alone as well as in combination increased GH concentrations, whereas a decrease in serum-free, but not total, IGF-I concentrations was observed.
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
Summary · context
We also performed a single-arm open label study under nonfasting conditions in five of these subjects.
Summary · context
After the second test either pegvisomant (80 mg as a single subcutaneous injection) or placebo was administered.
Summary · context
On day 4, GHRP-6 and GHRH tests were performed in the same order as on day 1.
Report a problemFND-1167882805
04HumanNon-randomized trialEfficacy outcome
In healthy lean men, serum total IGF-I concentrations did not decrease after pegvisomant alone.
In plain wordsIn healthy lean men, total IGF-I concentrations did not decrease after pegvisomant alone.
Peptide
Pegvisomant
Outcome
No significant changeSerum total IGF-I with pegvisomant alone
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 mg as a single injection · subcutaneousAs given in this study (human).
Source sentences
Summary
Three days of fasting alone and pegvisomant alone as well as in combination increased GH concentrations, whereas a decrease in serum-free, but not total, IGF-I concentrations was observed.
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
Summary · context
We also performed a single-arm open label study under nonfasting conditions in five of these subjects.
Summary · context
After the second test either pegvisomant (80 mg as a single subcutaneous injection) or placebo was administered.
Summary · context
On day 4, GHRP-6 and GHRH tests were performed in the same order as on day 1.
Report a problemFND-1167882806
05HumanNon-randomized trialEfficacy outcome
In healthy lean men, pegvisomant alone significantly increased GHRH-stimulated GH concentrations on day 4 compared with baseline.
In plain wordsIn healthy lean men, pegvisomant alone increased GH after GHRH on day 4 compared with baseline.
Peptide
Pegvisomant
Outcome
IncreaseGHRH-stimulated GH concentration on day 4
Study
n = 5
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 mg as a single injection · subcutaneousAs given in this study (human).
Source sentences
Summary
On day 4, fasting and pegvisomant, either alone or in combination, significantly increased GH concentrations after GHRH compared to baseline.
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
Summary · context
We also performed a single-arm open label study under nonfasting conditions in five of these subjects.
Summary · context
After the second test either pegvisomant (80 mg as a single subcutaneous injection) or placebo was administered.
Summary · context
On day 4, GHRP-6 and GHRH tests were performed in the same order as on day 1.
Report a problemFND-1167882807
06HumanNon-randomized trialEfficacy outcome
In healthy lean men, pegvisomant alone did not increase GH concentrations after GHRP-6 administration.
In plain wordsIn healthy lean men, pegvisomant alone did not increase GH concentrations after GHRP-6.
Peptide
Pegvisomant
Outcome
No significant changeGHRP-6-stimulated GH concentration with pegvisomant alone
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
80 mg as a single injection · subcutaneousAs given in this study (human).
Source sentences
Summary
Pegvisomant alone did not increase GH concentrations after GHRP-6 administration.
4 context sentences(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
Summary · context
We also performed a single-arm open label study under nonfasting conditions in five of these subjects.
Summary · context
After the second test either pegvisomant (80 mg as a single subcutaneous injection) or placebo was administered.
Summary · context
On day 4, GHRP-6 and GHRH tests were performed in the same order as on day 1.
Report a problemFND-1167882808

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

07HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In healthy lean men, pegvisomant alone did not increase GH concentrations after GHRP‑6 administration.
In plain wordsIn healthy lean men, pegvisomant alone did not raise growth hormone released in response to GHRP‑6.
Peptide
GHRP-6
Outcome
No significant changeGH after GHRP-6 with pegvisomant alone
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Pegvisomant alone did not increase GH concentrations after GHRP-6 administration.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1167882801
08HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In healthy lean men, fasting alone increased GH levels after GHRP‑6 administration.
In plain wordsIn healthy lean men, fasting raised the growth hormone released in response to GHRP‑6.
Peptide
GHRP-6
Outcome
IncreaseGH after GHRP-6 with fasting alone
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Fasting alone increased GH levels after GHRP-6 administration.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1167882802
09HumanNot a test of GHRP-6 aloneRandomized controlled trialEfficacy outcome
In healthy lean men, fasting combined with pegvisomant had a synergistic effect on GH release after GHRP‑6.
In plain wordsIn healthy lean men, fasting together with pegvisomant raised growth hormone released in response to GHRP‑6 more than expected from either alone.
Peptide
GHRP-6
Outcome
IncreaseGH after GHRP-6 with fasting plus pegvisomant
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The combination of fasting and pegvisomant had a synergistic effect on GH release after GHRP-6.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a double-blind placebo-controlled cross-over study comparing the effects of pegvisomant and fasting on the GH-releasing hormone (GHRH)- and GH-releasing peptide-6 (GHRP-6)-stimulated GH-release before and after 3 days of fasting in 10 healthy lean male subjects.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1167882803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 3
27 Oct 2026, 16:34 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.